Best Practice & Research Clinical Rheumatology
Volume 20, Issue 3 , Pages 435-450 , June 2006

Psoriatic arthritis: One or more diseases?

  • Oliver FitzGerald, MD FRCPI FRCP (UK) (Newman Clinical Research Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +353 1 2773721; Fax: +353 1 2697949.

References 

  1. Berthelot JM. Psoriatic arthritis as a mountain. Reumatismo. 2003;55:6–15
  2. Goupille P. Psoriatic arthritis. Joint Bone Spine. 2005;76:466–470
  3. Guillemin F, Saraux A, Guggenbuhl P, et al. Prevalence of rheumatoid arthritis in France: 2001. Annals of the Rheumatic Diseases. 2005;64:1427–1430
  4. Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France: 2001. Annals of the Rheumatic Diseases. 2005;64:1431–1435
  5. Gladmann DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases. 2005;64:ii14–ii17
  6. van Rommunde LKJ, Valkenburg HA, Swart-Bruinsma W, et al. Psoriasis and arthritis. I. A population study. Rheumatology International. 1984;4:55–60
  7. Amor B, Dougados M, Listrat V, et al. Evaluation of the Amor criteria for spondylarthropathies and European Spondylarthropathy Study Group (ESSG). A cross-sectional analysis of 2.228 patients. Annales de Medecine Interne (Paris). 1991;142:85–89
  8. Harrison BJ, Silman AJ, Barrett EM, et al. Presence of psoriasis does not influence the presentation of short-term outcome of patients with early inflammatory polyarthritis. The Journal of Rheumatology. 1997;24:1744–1747
  9. Morgan C, Lunt M, Bunn D, et al. Similar outcome at 5 years in inflammatory arthritis patients with and without psoriasis. Arthritis and Rheumatism. 2005;52(supplement):S120;[Abstr 235]
  10. Stafford L, Kane D, Murphy E, et al. Psoriasis predicts a poor short-term outcome in patients with spondylarthropathies. Arthritis and Rheumatism. 2001;45:485–493
  11. Wright V. Rheumatism and psoriasis: a re-evaluation. The American Journal of Medicine. 1959;3:71–78
  12. Moll JMH, Wright V. Psoriatic arthritis. Seminars in Arthritis and Rheumatism. 1973;3:51–78
  13. McHugh NJ, Balachrishman C, Jones SM. Progression of periphetal joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42:778–783
  14. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460–1468
  15. Dougados M. Synovial fluid cell analysis. Baillière's Clinical Rheumatology. 1996;10:519–534
  16. Berthelot JM, Klarlund M, McGonagle D, et al. Lessons from an international survey of paper cases of 10 real patients from an early arthritis clinic. The Journal of Rheumatology. 2001;28:975–981
  17. Rothschild M, Pingitore C, Eaton M. Dactylitis: implications for clinical practice. Seminars in Arthritis and Rheumatism. 1998;28:41–47
  18. Olivieri I, Barozzi L, Favaro L, et al. Dactylitis in patients with seronegative spondylarthropathies. Assessment by ultrasonography and magnetic resonance imaging. Arthritis and Rheumatism. 1996;39:1524–1528
  19. Helliwell PS, Marchesoni A, Peters M, Barker M, Wright V. A re-evaluation of the osteoarticular manifestations of psoriasis. British Journal of Rheumatology. 1991;30:339–345
  20. Gladman DD, Shuckett R, Russel ML, et al. Psoriatic arthritis (PSA)—an analysis of 220 patients. Quarterly Journal of Medicine. 1987;238:127–141
  21. McEwen C, Di Tata D, Lingg C, et al. A comparative study of ankylosing spondylitis and spondylitis accompanying ulcerative colitis, regional enteritis, psoriasis and Reiter's disease. Arthritis and Rheumatism. 1971;14:291–318
  22. Helliwell PS, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis?. Annals of the Rheumatic Diseases. 1998;57:135–140
  23. Le Goff P, Brousse A, Fauquert P, et al. Anterior thoracic and intervetebral erosive joint diseases associated with palmoplantal pustulosis. Revue du Rhumatisme et des Maladies Osteo-articulaires. 1985;52:391–396
  24. Eastmond CJ, Wright V. The mail dystrophy of psoriatic arthritis. Annals of the Rheumatic Diseases. 1979;38:226–228
  25. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. The Journal of Rheumatology. 1986;13:586–592
  26. Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthritis. The Journal of Rheumatology. 1992;19:1724–1726
  27. Taylor WJ, Marchesoni A, Arreghini M, et al. A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. Seminars in Arthritis and Rheumatism. 2004;34:575–584
  28. Moll JMH, Wright V. Psoriatic arthritis. Seminars in Arthritis and Rheumatism. 1973;3:55–78
  29. Biondi Oriente C, Scarpa R, Pucino A, Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Dermato-venereologica Supplementum. 1989;146:69–71
  30. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. British Journal of Rheumatology. 1991;30:245–250
  31. Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. British Journal of Rheumatology. 1994;33:834–839
  32. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. British Journal of Rheumatology. 1994;33:133–138
  33. Vasey FB, Espinoza LR. Psoriatic arthritis. In:  Calin A editors. Spondyloarthropathies. Orlando: Grune and Stratton; 1984;p. 151–185
  34. Fournie B, Crognier L, Arnaud C, et al. Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients. Revue du Rhumatisme English Edition. 1999;66:446–456
  35. Helliwel PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Annals of the Rheumatic Diseases. 2005;64:ii3–ii8
  36. van der Heijde D, Bellamy N, Calin A, et al. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in ankylosing spondylitis working group. The Journal of Rheumatology. 1997;24:2225–2229
  37. Clegg DD, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo for the treatment of psoriatic arthritis and cutaneous psoriasis. Arthritis and Rheumatism. 1996;39:2013–2020
  38. Helliwel PS, Firth J, Ibrahim GH, et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. The Journal of Rheumatology. 2005;32:1745–1750
  39. Kyle S, Chandler D, Griffiths CEM, et al. Guideline for anti-TNF-α therapy in psoriatic arthritis. Rheumatology. 2005;44:390–397
  40. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000;356:385–390
  41. Antoni C, Kavanaugh A, Kirkham B, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis and Rheumatism. 2002;46:S381
  42. EMEA: http://www.emea.eu.int/pdfs/human/ewp/489103en.pdf
  43. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. The Journal of Investigative Dermatology. 2003;120:211–216
  44. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Archives of Dermatology. 1998;134:1582
  45. Nair RP, Stuart P, Henseler T, et al. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. American Journal of Human Genetics. 2000;66:1833–1844
  46. Schmitt-Egenolf ME, Eiermann TH, Boehncke WH, et al. Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57- DRB1*0701-DQA1*0201-DQB1*0303: a population- and family-based study. The Journal of Investigative Dermatology. 1996;106:711–714
  47. Trembath RC, Clough RL, Rosbotham RL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Human Molecular Genetics. 1997;6:813–820
  48. Curran SA, FitzGerald OM, Costello PJ, et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing antigen. Journal of Immunology. 2004;172:1935–1944
  49. Espinoza LR, Berman A, Vasey FB, et al. Psoriatic arthritis and acquired immunodeficiency syndrome. Arthritis and Rheumatism. 1998;31:1034–1040
  50. Orru S, Giuressi E, Carcassi C, et al. Mapping of the major psoriasis-susceptibility locus (PSORS1) in a 70-Kb interval around the corneodesmosin gene (CDSN). American Journal of Human Genetics. 2005;76:164–171
  51. Tazi Ahnini R, Camp NJ, Cork MJ, et al. Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. Human Molecular Genetics. 1999;8:1135–1140
  52. Balding J, Kane D, Livingstone W, et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis and Rheumatism. 2003;48:1408–1413
  53. Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005;437:369–375
  54. Johansen C, Kragballe K, Rasmussen M, et al. Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. The British Journal of Dermatology. 2004;151:600–607
  55. Gonzalez S, Martinez-Borra J, Lopez-Vazquez A, et al. MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. The Journal of Rheumatology. 2002;29:973–978
  56. Karason A, Gudjonsson JE, Upmanyu R, et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. American Journal of Human Genetics. 2003;72:125–131
  57. Bos JD, de Rie MA, Teunissen MB, Piskin G. Psoriasis: dysregulation of innate immunity. The British Journal of Dermatology. 2005;152:1098–1107
  58. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. The Journal of Experimental Medicine. 1993;178:1271–1281
  59. McKay IA, Leigh IM. Altered keratinocyte growth and differentiation in psoriasis. In pathogenic aspects of psoriasis. Clinical Dermatology. 1995;105–114
  60. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunology Today. 1999;20:40–46
  61. Paukkonen K, Naukkarinen A, Horsmanheimo M. The development of manifest psoriatic lesions is linked with the invasion of CD8+ T cells and CD11c+ macrophages into the epidermis. Archives of Dermatological Research. 1992;284:375–379
  62. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1:442–447
  63. Cameron AL, Kirby B, Fei W, Griffiths CE. Natural killer and natural killer-T cells in psoriasis. Archives of Dermatological Research. 2002;294:363–369
  64. Nickoloff BJ, Bonish B, Huang BB, Porcelli SA. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. Journal of Dermatological Science. 2000;24:212–225
  65. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Research & Therapy. 2005;7:R569–R580
  66. Zhou X, Krueger JG, Kao MC, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiological Genomics. 2003;13:69–78
  67. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374
  68. Nomura I, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. Journal of Immunology. 2003;171:3262–3269
  69. Kane D, Gogarty M, O'Leary J, et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis and Rheumatism. 2004;50:3286–3295
  70. Baker BS, Ovigne JM, Powles AV, et al. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. The British Journal of Dermatology. 2003;148:670–679
  71. Veale DY, Rogers S, Barnes L, et al. Reduced synovial membrane ELAM-1 expression, macrophage numbers and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis and Rheumatism. 1993;36:893–900
  72. Pitzalis C, Cauli A, Pipitone N, et al. Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis and Rheumatism. 1996;39:137–145
  73. Reece RC, Parsons W, Emery P, Veale DJ. Distinct vascular patterns in the synovitis of psoriatic, reactive and rheumatoid arthritis. Arthritis and Rheumatism. 1999;42:1481–1485
  74. Fraser A, Fearon U, Reece R, et al. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis and Rheumatism. 2001;44:2024–2028
  75. Kruithof E, De Rycke L, De Keyser F et al. Indentification of synovial biomarkers of response to treatment in Spondyloarthropathy. Arthritis and Rheumatism; in press.
  76. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Annals of the Rheumatic Diseases. 2004;63:769–773
  77. Danning CL, Illei GG, Hitchon C, et al. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis and Rheumatism. 2000;43:1244–1256
  78. Ralph JA, McEvoy AN, Kane D, et al. Modulation of orphan nuclear receptor NURR1 expression by methotrexate in human inflammatory joint disease involves adenosine A2A receptor-mediated responses. Journal of Immunology. 2005;175:555–565

PII: S1521-6942(06)00029-5

doi: 10.1016/j.berh.2006.02.002

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 3 , Pages 435-450 , June 2006

Article Tools